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 COPD is a serious public health problem in the United States. In 2008, chronic lower respiratory 
diseases, of which COPD represents the principal 
component, became the third leading cause of mor-
tality. 1 Because smoking is the dominant risk factor 
for COPD and contributed to about 80% of COPD 
deaths in 2000 to 2004, 2 much of this disease is poten-
tially preventable. People with COPD experience 
worse health-related quality of life, more disabilities, 
and higher rates of comorbidities than people with-
out COPD. 3-5 The direct economic cost attributable 
to COPD and asthma in 2008 has been estimated 
at $53.7 billion in the United States. 6 These costs 
 This report updates surveillance results for COPD in the United States. For 1999 to 2011, data 
from national data systems for adults aged   25 years were analyzed. In 2011, 6.5% of adults 
(approximately 13.7 million) reported having been diagnosed with COPD. From 1999 to 2011, 
the overall age-adjusted prevalence of having been diagnosed with COPD declined ( P  5 .019). 
In 2010, there were 10.3 million (494.8 per 10,000) physician ofﬁ ce visits, 1.5 million (72.0 per 
10,000) ED visits, and 699,000 (32.2 per 10,000) hospital discharges for COPD. From 1999 to 
2010, no signiﬁ cant overall trends were noted for physician ofﬁ ce visits and ED visits; however, 
the age-adjusted hospital discharge rate for COPD declined signiﬁ cantly ( P  5 .001). In 2010 there 
were 312,654 (11.2 per 1,000) Medicare hospital discharge claims submitted for COPD. Medicare 
claims (1999-2010) declined overall ( P  5 .045), among men ( P  5 .022) and among enrollees aged 
65 to 74 years ( P  5 .033). There were 133,575 deaths (63.1 per 100,000) from COPD in 2010. The 
overall age-adjusted death rate for COPD did not change during 1999 to 2010 ( P  5 .163). Death 
rates (1999-2010) increased among adults aged 45 to 54 years ( P  , .001) and among American 
Indian/Alaska Natives ( P  5 .008) but declined among those aged 55 to 64 years ( P  5 .002) and 65 
to 74 years ( P  , .001), Hispanics ( P  5 .038), Asian/Paciﬁ c Islanders ( P  , .001), and men ( P  5 .001). 
Geographic clustering of prevalence, Medicare hospitalizations, and deaths were observed. 
Declines in the age-adjusted prevalence, death rate in men, and hospitalizations for COPD since 
1999 suggest progress in the prevention of COPD in the United States.
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Furthermore, prevalence estimates of obstructive impairment 
using recent National Health and Nutrition Examination Survey data 
have been published. 14 Except for Medicare hospital claims, the 
data presented in this report are limited to adults aged   25 years, 
to remain consistent with the prior surveillance report. Because 
all the data that were used in the analyses are freely available in 
the public domain, our study was exempt from human subject 
review. 
 Behavioral Risk Factor Surveillance System 
 BRFSS data from 2011 were used to estimate the state speciﬁ c 
and US prevalence of COPD. An annual sample representing the 
noninstitutionalized US adult population aged   18 years in each 
state was selected by state health departments in collaboration 
with the CDC using a complex multistage sampling design. 15 Data 
from 475,616 respondents aged   25 years were analyzed for this 
report. The BRFSS is a random-digit-dialed telephone survey of 
landline and cellphone households, and one adult is selected for 
the telephone interview. The median survey response rate in 2011 
for all states and the District of Columbia was 49.7% and ranged 
from 33.8% to 64.1%. The median cooperation rate (percentage 
of people who completed interviews among all eligible contacted 
people) was 74.2% and ranged from 52.7% to 84.3%. The follow-
ing question was used to deﬁ ne COPD: “Have you ever been told 
by a doctor or other health professional that you have chronic 
obstructive pulmonary disease (COPD), emphysema, or bronchitis?” 
An afﬁ rmative response was deﬁ ned as physician-diagnosed COPD. 
Demographic information was self-reported. 
 National Health Interview Survey 
 NHIS data from 1999 to 2011 were used to estimate the prev-
alence of COPD. 16 The NHIS is implemented annually by the 
National Center for Health Statistics, CDC. During each year, a 
sample representing the civilian, noninstitutionalized US population 
aged   18 years was selected by using a complex multistage sam-
pling design that involves stratiﬁ cation, clustering, and oversampl-
ing. The universe of primary sampling units (PSUs) (single counties 
or groups of adjacent counties—or equivalent jurisdictions—or 
metropolitan area) is organized into strata from which a sample of 
PSUs representing areas is drawn. From substrata (census blocks 
or combined blocks) created in these selected PSUs, secondary 
sampling units are systematically selected. From each substra-
tum, households with African American, Hispanic, and Asian 
(since 2006) were oversampled, and a sample of all other house-
holds was selected. Only one randomly selected adult per family 
was asked to participate in the Sample Adult questionnaire. Par-
ticipants were visited in their homes, where US Census Bureau 
interviewers conducted a computer-assisted personal interview 
with the participants. The number of adult participants and the 
response rates of the surveys are summarized in e-Table 1. Data 
from adult respondents aged   25 years were analyzed for this 
report. The following two questions were used to deﬁ ne COPD: 
“Have you ever been told by a doctor or other health professional 
that you had emphysema?” and “During the past 12 months, have 
you been told by a doctor or other health professional that you 
had chronic bronchitis?” An afﬁ rmative response to one or both 
of these questions was deﬁ ned as physician-diagnosed COPD for 
this report. Demographic information was self-reported. 
 National Ambulatory Medical Care Survey 
 NAMCS data from 1999 to 2010 were used to estimate the 
annual number of physician ofﬁ ce visits with the ﬁ rst-listed diag-
nosis of COPD. 17 The NAMCS is an annual, national probability 
sample survey of ambulatory visits to nonfederally employed 
ofﬁ ce-based physicians conducted by the National Center for 
include those for prescription medicines ($20.4 billion), 
outpatient or ofﬁ ce-based providers ($13.2 billion), 
hospital inpatient stays ($13.1 billion), home health 
care ($4.0 billion), and ED visits ($3.1 billion). 
 COPD consists of chronic bronchitis, emphysema, 
and small airways disease. This common lung disease 
is characterized by inﬂ ammation and thickening of 
the mucosae of the airways, weakening or destruction 
of alveolar walls, and excess mucus production. These 
mechanical and physiologic changes lead to airﬂ ow 
limitation with limited reversibility. Patients affected 
by this disorder may be asymptomatic or experience 
cough, dyspnea, wheezing, and chest tightness. With 
progression of the disease, dyspnea worsens and oxy-
genation impairment develops. As the capacity of the 
lung continues to decline, patients may have increas-
ing difﬁ culty in performing activities of daily living. 
Although the clinical course of COPD is variable, it is 
progressive in many patients. Increasingly, research 
is examining the relationships between COPD and 
comorbid disease. 7,8 
 The condition has a diverse etiology. 4,9 Although 
smoking is the chief cause of COPD in most popula-
tions, substantial proportions of COPD occur among 
nonsmokers. 10-12 Other important causes include indoor 
air pollution from burning of biomass, occupational 
exposures to a variety of dusts and smoke, asthma, 
and repeated respiratory infections. In addition, genetic 
causes, such as  a 1 -antitrypsin deﬁ ciency, can result in 
emphysema. 
 In 2002, the Centers for Disease Control and Pre-
vention (CDC) released the initial surveillance report 
about COPD that contained surveillance data through 
the year 2000. 13 This report summarized data from 
national data systems regarding prevalence, physician 
outpatient visits, ED visits, hospitalizations, and mor-
tality. Of note was that the age-adjusted mortality rate 
had increased from 1980 to 2000, especially in women. 
The current surveillance report seeks to characterize 
recent aspects of the burden of COPD by providing 
additional information from national datasets through 
2011. 
 Materials and Methods 
 The following data sources were used to produce the esti-
mates in this report: Behavioral Risk Factor Surveillance Sys-
tem (BRFSS) (2011), National Health Interview Survey (NHIS) 
(1999-2011), National Ambulatory Medical Care Survey (NAMCS) 
(1999-2010), National Hospital Ambulatory Medical Care Survey 
(NHAMCS) (1999-2010), National Hospital Discharge Survey 
(NHDS) (1999-2010), death certiﬁ cate data from the National 
Vital Statistics System (NVSS) (1999-2010), and Medicare Part 
A hospital claims administrative data (1999-2010). We did not 
include data from the National Health and Nutrition Examination 
Survey in this report because data from NHIS has commonly been 
used to provide national estimates of the prevalence of COPD. 
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Health Statistics, CDC. Beginning in 2006, visits to Community 
Health Centers (CHCs) were also included. NAMCS used a mul-
tistage design that involved probability samples of PSUs, physicians 
within PSUs, and patient visits within practices. The ﬁ rst-stage 
sample included 112 PSUs. In each sample PSU, a probability 
sample of practicing nonfederal ofﬁ ce-based physicians was 
selected from master ﬁ les maintained by the American Medical 
Association and American Osteopathic Association. The ﬁ nal stage 
involved systematic random samples of ofﬁ ce visits during ran-
domly assigned 7-day reporting periods. Starting in 2006, a dual-
sampling procedure was used to select CHC physicians and other 
providers. First, the traditional NAMCS sample was selected using 
the methods described previously. Second, information from the 
Health Resources and Services Administration and the Indian 
Health Service was used to select a sample of CHCs. Within 
CHCs, a maximum of three health-care providers were selected, 
including physicians, physician assistants, nurse practitioners, or 
nurse midwives. After selection, CHC providers followed tradi-
tional NAMCS methods for selecting patient visits. The physician-
patient encounter or visit represents the basic sampling unit in 
NAMCS. 
 Data are collected by the physician or the physician’s staff or by 
US Census Bureau ﬁ eld representatives. Information concerning 
race and ethnicity was based on the physician’s knowledge of the 
patient or on the physician’s or assistant’s judgment rather than 
the patient self-report. The number of physician ofﬁ ce visits and 
the physicians’ response rates are shown in e - Table 2. Because the 
percent of ofﬁ ce visit medical records that were missing race 
information ranged from 16.9% to 32.8% (e-Table 2), we used 
 Table 2— Estimated Number and Prevalence of 
Self-Reported, Physician-Diagnosed COPD 
(Ever COPD, Chronic Bronchitis, or Emphysema) 
Among Adults Aged   25 Years, By State—United 
States, Behavioral Risk Factor Surveillance 
System, 2011 
State
Estimated 
No. a Age-Adjusted, b,c % Unadjusted, % c 
Alabama 330,000 9.9 10.4
Alaska 24,000 6.1 5.5
Arizona 253,000 5.8 6.1
Arkansas 171,000 8.1 8.9
California 1,073,000 4.7 4.9
Colorado 167,000 5.1 5.0
Connecticut 155,000 6.1 6.5
Delaware 35,000 5.4 5.8
District of 
Columbia
20,000 5.0 4.9
Florida 1,086,000 7.5 8.4
Georgia 462,000 7.4 7.4
Hawaii 43,000 4.5 4.7
Idaho 58,000 5.7 5.9
Illinois 549,000 6.4 6.6
Indiana 390,000 8.9 9.3
Iowa 109,000 5.0 5.5
Kansas 134,000 6.9 7.3
Kentucky 306,000 10.1 10.6
Louisiana 213,000 7.0 7.3
Maine 79,000 7.5 8.5
Maryland 239,000 6.1 6.2
Massachusetts 283,000 6.0 6.4
Michigan 574,000 8.2 8.8
Minnesota 148,000 4.1 4.2
Mississippi 170,000 8.6 9.0
Missouri 353,000 8.3 8.9
Montana 44,000 6.0 6.6
Nebraska 65,000 5.2 5.5
Nevada 143,000 7.9 8.1
New Hampshire 61,000 6.4 6.9
New Jersey 329,000 5.3 5.6
New Mexico 92,000 6.5 6.9
New York 822,000 6.0 6.3
North Carolina 458,000 6.9 7.3
North Dakota 21,000 4.5 5.0
Ohio 646,000 7.9 8.4
Oklahoma 225,000 8.6 9.3
Oregon 168,000 5.9 6.5
Pennsylvania 626,000 6.7 7.3
Rhode Island 49,000 6.5 7.0
South Carolina 252,000 7.7 8.2
South Dakota 31,000 5.2 5.9
Tennessee 391,000 8.6 9.2
Texas 928,000 6.0 5.9
Utah 68,000 4.4 4.3
Vermont 24,000 4.9 5.6
Virginia 363,000 6.6 6.8
Washington 205,000 4.4 4.5
West Virginia 124,000 8.8 9.7
Wisconsin 219,000 5.4 5.8
Wyoming 25,000 6.2 6.7
Total 13,724,000 6.5 6.8
 a Numbers may not add to total because of rounding.
 b Age-adjusted to the 2000 US standard population aged   25 y.
 c All relative SEs are   30%.
 Table 1— Estimated Number and Prevalence of 
Self-Reported, Physician-Diagnosed COPD 
(Ever COPD, Chronic Bronchitis, or Emphysema) 
Among Adults Aged   25 Years, by Race, Sex, and 
Age Group—United States, Behavioral Risk Factor 
Surveillance System, 2011 
Characteristics 
Estimated 
No. a Age-Adjusted, b,c % Unadjusted, % c 
Race/ethnicity
 White, 
 non-Hispanic
10,460,000 6.9 7.6
 Black, 
 non-Hispanic
1,418,000 6.5 6.4
 Hispanic 1,030,000 4.1 3.6
 Asian/Paciﬁ c 
 Islander
173,000 2.5 2.2
 American 
  Indian/Alaska 
Native
247,000 11.0 11.5
 Other, 
 non-Hispanic
397,000 11.2 11.3
Sex
 Women 8,197,000 7.3 7.8
 Men 5,681,000 5.7 5.8
Age group, y
 25-44 2,755,000 … 3.4
 45-54 2,913,000 … 6.6
 55-64 3,263,000 … 9.2
 65-74 2,719,000 … 12.1
   75 2,227,000 … 11.6
Total 13,724,000 6.5 6.8
 a Numbers for each variable may not add to total because of rounding.
 b Age-adjusted to the 2000 US standard population aged   25 y.
 c All relative SEs are   30%.
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information for race (whites and blacks only) that was imputed 
by the National Center for Health Statistics. 
 Three visit diagnosis fields were available to participating 
physicians. A diagnosis of COPD was established from the  Inter-
national Classiﬁ cation of Diseases, Ninth Revision, Clinical Modiﬁ ca-
tion (ICD-9-CM) codes 490 (bronchitis not speciﬁ ed as acute or 
chronic), 491 (chronic bronchitis), 492 (emphysema), or 496 (chronic 
airway obstruction, not elsewhere classiﬁ ed, which includes COPD) 
for the ﬁ rst-listed diagnosis. Rates for ofﬁ ce visits were calculated 
using US civilian population estimates provided in the data ﬁ le 
documentation for each year (e-Table 3). SEs were produced with 
statistical software. 
 National Hospital Ambulatory Medical Care Survey 
 NHAMCS data for the years 1999 to 2010 were used to esti-
mate the number of ED visits for COPD. 17 The NHAMCS is an 
annual, national probability sample survey of ambulatory visits made 
to nonfederal, general, short-stay hospitals in the US conducted 
by the National Center for Health Statistics, CDC. NHAMCS 
uses a multistage probability design with samples of PSUs, hospi-
tals within PSUs, EDs plus clinics within outpatient departments, 
and patient visits within EDs and outpatient clinics. Sample hos-
pitals are randomly assigned to 16 panels that rotate across 13 
4-week reporting periods throughout the year. The initial sample 
frame of hospitals was based on the 1991 SMG hospital database 
now maintained by IMS Health Incorporated. Hospital staff or 
US Census Bureau ﬁ eld representatives performed data collec-
tion for NHAMCS. The annual number of patient record forms 
submitted by EDs is shown in e-Table 4. 
 The NHAMCS ﬁ les contained three visit diagnosis ﬁ elds. An 
ICD-9-CM code of 490-492 or 496 for the ﬁ rst-listed diagnosis 
was deﬁ ned as an ED visit for COPD. Because the percentage 
of ED records that were missing race information ranged from 
10.4% to 15.3% (e-Table 4), we used information for race (whites 
and blacks only) that was imputed by the National Center for 
Health Statistics. The US civilian population estimates that we 
used to calculate rates of ED visits were obtained from the data 
ﬁ le documentation for each year (e-Table 3). SEs were produced 
with statistical software. 
 National Hospital Discharge Survey 
 NHDS data from 1999 to 2010 were used to estimate the 
annual number of hospital discharges for COPD. 18 NHDS is an 
annual survey of inpatient discharges from nonfederal, short-stay 
hospitals in the US conducted from 1965 to 2010 by the National 
Center for Health Statistics, CDC. Using the SMG Hospital Market 
 Figure 1. Age-adjusted prevalence (%) of self-reported physician-
diagnosed COPD among adults aged   25 years, by state—United 
States, Behavioral Risk Factor Surveillance System, 2011 . 
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 Using the ﬁ rst-listed diagnosis, hospital discharges for COPD 
were identiﬁ ed by using the ICD-9-CM codes 490-492 or 496 
as the ﬁ rst-listed diagnosis or ICD-9-CM code 466-466.1 (acute 
bronchitis) if the first-listed diagnosis of acute bronchitis was 
accompanied by another listed diagnosis of COPD (490-492 
or 496). The percent of hospital records missing race infor-
mation ranged from 16.0% to 31.0% (e-Table 5). US civilian 
population estimates used to calculate hospital discharge rates 
were obtained from the NHDS data documentation (e-Table 6). 
Relative SEs were calculated from the following formula: 
RSE(X)  5 (a  1 b/X) 1/2 , where a and b represent coefﬁ cients pro-
vided in the data documentation, and X represents the number 
of discharges. 
Data File or its successors as the sampling frame, the NHDS sam-
ples inpatient discharges from nonfederal, general, short-stay hos-
pitals located in the 50 states and the District of Columbia. A 
three-stage design has been used since 1988. Units selected at the 
ﬁ rst stage of sampling consisted of either hospitals or geographic 
areas, such as counties, groups of counties, or metropolitan statis-
tical areas in the 50 states and the District of Columbia. Within 
sampled geographic areas, additional hospitals were selected. 
Finally, at the last stage, discharges were selected within the sam-
pled hospitals using systematic random sampling. Data collection 
was performed with manual and automated systems. The annual 
number of sampled records and hospital response rates are pro-
vided in e-Table 5. 
 Table 4— Estimated Annual Prevalence of Self-Reported Physician-Diagnosed COPD (Lifetime Emphysema or 
Chronic Bronchitis During the Preceding 12 Months) Among Adults Aged   25 Years, by Race/Ethnicity, Sex, and Age 
Group—United States, National Health Interview Survey, 1999-2011 
Variable 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011  P for Linear Trend
Race a 
 White, non-Hispanic 6.1 6.6 7.5 6.2 5.7 6.3 6.1 6.3 5.4 6.4 6.7 6.1 6.0 .130
 Black, non-Hispanic 4.3 5.4 6.3 6.0 5.0 4.8 5.2 5.4 4.2 4.6 5.3 5.5 6.2 .443
 Hispanic 3.6 3.9 4.3 3.7 3.6 3.9 3.3 3.5 3.3 3.1 4.1 3.9 4.3 .805
 Other, non-Hispanic 4.0 2.8 3.9 3.2 3.3 3.6 2.9 4.1 2.9 3.1 3.4 3.1 3.9 .626
Sex a 
 Women 6.7 7.3 8.1 6.9 6.3 6.8 6.6 6.7 5.6 6.9 7.1 6.5 7.0 .136
 Men 4.6 4.8 5.6 4.8 4.3 4.5 4.6 4.9 4.1 4.3 4.9 4.7 4.3 .063
Age group, y
 25-44 3.7 3.9 4.8 3.9 3.1 3.6 3.5 3.1 2.6 3.4 3.2 3.3 3.2  , .001
 45-54 5.1 5.9 7.0 5.9 4.9 5.6 5.4 5.7 4.7 6.2 6.3 5.4 5.6 .655
 55-64 7.5 8.0 8.8 7.9 7.7 7.1 7.3 8.8 7.2 7.0 8.4 7.7 8.2 .929
 65-74 9.2 9.6 10.0 9.5 9.9 9.3 10.0 8.9 8.4 9.6 10.3 9.5 10.3 .566
   75 9.8 10.6 11.0 8.6 8.8 10.2 9.1 11.1 8.7 9.0 11.1 10.3 9.0 .679
Total a 5.7 6.1 6.9 5.9 5.3 5.7 5.6 5.8 4.9 5.6 6.0 5.7 5.7 .019
Total b 5.6 6.0 6.9 5.9 5.3 5.7 5.6 5.9 5.0 5.8 6.2 5.8 5.9 .372
Annual prevalence per 100 population. All relative SEs are   30%.
 a Age-adjusted to the 2000 US standard population aged   25 y.
 b Unadjusted prevalence.
 Figure 2. Age-adjusted prevalence (%) of self-reported physician-diagnosed COPD among adults 
aged   25 years, by sex and year—United States, National Health Interview Survey, 1999-2011. 
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 Medicare Part A Hospital Claims 
 Medicare data from 1999 to 2010 were used to estimate the 
annual number of hospital discharges for COPD among Medi-
care enrollees aged   65 years. Hospitalization information from 
100% of Medicare Part A hospital claims data were obtained from 
an administrative claims dataset maintained by the Centers for 
Medicare and Medicaid Services. Information was limited to approxi-
mately 10 million annual claims submitted for short-term fee-for-
service hospital stays among Medicare enrollees aged   65 years 
residing in one of the 50 states or the District of Columbia in a 
given year. A hospital discharge for COPD was deﬁ ned for a 
ﬁ rst-listed discharge diagnosis with ICD-9-CM codes 490-492 or 
496—about 3% of annual Medicare claims. Few Medicare claims 
( , 0.05%) were submitted for acute bronchitis (ICD-9-CM code 
466-466.1) with concomitant COPD; therefore, we did not include 
these discharges in our analyses. Race/ethnicity information on 
the claims data for Medicare enrollees represents information 
provided by most Medicare enrollees at the time of enrollment 
into the Medicare system or is information updated for older 
enrollees. Less than 0.5% of COPD claims were missing race 
information. State of residence was also obtained from the claims 
data. Medicare enrollment records were obtained from the Cen-
ters for Medicare and Medicaid Services and were used as the 
denominator ﬁ le to calculate hospital rates after restricting the 
denominator to Medicare enrollees who met all the following 
 Figure 3. Sex-speciﬁ c age-adjusted rates (per 10,000 US civil-
ian population) of physician office visits, ED visits, and hospi-
tal visits for COPD as the ﬁ rst-listed diagnosis among adults 
aged   25 years—United States, National Ambulatory Medical 
Care Survey, National Hospital Ambulatory Medical Care Survey, 
National Hospital Discharge Survey, 2010. 
 Figure 4. Race-speciﬁ c age-adjusted rates (per 10,000 US civil-
ian population) of physician office visits, ED visits, and hospi-
tal visits for COPD as the ﬁ rst-listed diagnosis among adults 
aged   25 years—United States, National Ambulatory Medical Care 
Survey, National Hospital Ambulatory Medical Care Survey, National 
Hospital Discharge Survey, 2009-2010. 
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criteria on July 1 of any given year (alive, aged   65 years, entitled 
to Part A beneﬁ ts, residing in one of the 50 states or the District 
of Columbia, and not enrolled in a managed care plan). 
 National Vital Statistics System 
 The number of deaths with COPD as the underlying cause for 
the years 1999 to 2010 come from the NVSS and are made avail-
able from CDC’s WONDER system (Compressed Mortality File). 19 
This interactive Web-based tool allows queries to obtain numbers 
of death for underlying causes, crude death rates, age-adjusted 
death rates, 95% CIs, and SEs for groups deﬁ ned by various char-
acteristics including year, place of residence (state, county, region, 
or division), sex, age group, race, and Hispanic origin. 20 Data from 
the NVSS are based on information from all resident death certiﬁ -
cates ﬁ led in the 50 States and the District of Columbia. Cause-of-
death statistics presented in this report are classiﬁ ed in accordance 
with the  International Classiﬁ cation of Diseases, Tenth Revision 
(ICD-10). ICD-10 codes J40-J44 were used to identify deaths 
from COPD as the underlying cause of death. These causes 
include chronic bronchitis (J40-J42), emphysema (J43), and other 
COPD (J44). 
 Mortality rates were calculated by using population estimates 
produced by the Bureau of the Census in collaboration with the 
National Center for Health Statistics. 20 The 1999 population esti-
mates are US Census Bureau bridged-race intercensal estimates 
of the July 1 resident population, based on the 1990 census and 
the bridged-race 2000 census. The 2000 and 2010 population esti-
mates are April 1 modiﬁ ed 2000 and 2010 census counts with 
bridged-race categories, whereas the 2001 to 2009 population 
estimates are bridged-race intercensal estimates of July 1 resident 
populations, based on the year 2000 and the year 2010 census 
counts (released by CDC on October 26, 2012). Age-adjusted 
death rates for 2001 to 2009 may vary from previous reports because 
of the 2012 revision of the 2001 to 2009 population denominator 
estimates. 
 Data Analysis 
 SAS-callable SUDAAN (Research Triangle Institute) was used 
to obtain weighted US estimates and prevalence from NHIS and 
state-speciﬁ c and US estimates and prevalence from BRFSS. 
SAS or SAS-callable SUDAAN analyses for data from NAMCS, 
NHAMCS, and NHDS were weighted to obtain national US esti-
mates. SAS was also used to obtain the number of COPD hospital 
discharges from Medicare hospital claims. The reported numbers 
of deaths, age-speciﬁ c death rates, and age-adjusted death rates 
from COPD were obtained from CDC WONDER. 19 Estimates 
were produced for all adults aged   25 years as well as for groups 
deﬁ ned by age (25-44, 45-54, 55-64, 65-74, and   75 years), sex, and 
race/ethnicity. Racial/ethnic categories varied between surveil-
lance systems because of differences in Medicare deﬁ nitions of 
race/ethnicity categories; absence of racial/ethnic information on 
many medical records abstracted for NAMCS, NHAMCS, and 
NHDS; or small numbers of NHIS respondents in some racial/eth-
nic categories in the population samples selected. Except for Medi-
care estimates, age-adjusted estimates were standardized to the 
2000 standard US population aged   25 years using the direct 
method. 21 Medicare estimates were age-standardized to the 2000 
standard US population aged   65 years. Because of the well-
known relationship between age and COPD and because of the 
aging of the US population, we calculated age-adjusted estimates 
of prevalence and rates. State-speciﬁ c age-adjusted estimates for 
BRFSS prevalence, Medicare hospitalizations, and mortality for 
COPD were also obtained to examine geographic clustering of 
COPD burden. 
 The statistical signiﬁ cance of temporal trends for age-speciﬁ c 
prevalence of COPD in NHIS was examined by using log-linear 
regression analysis with time as the independent variable; analyses 
for trends in the age-adjusted prevalence included age as a contin-
uous variable. The statistical signiﬁ cance for linear trends in age-
speciﬁ c and age-adjusted rates of physician-ofﬁ ce visits, ED visits, 
NHDS and Medicare hospitalizations, and mortality was exam-
ined using weighted least-squares regression, where the weights 
were the inverse of the squared SE. 
 Results 
 Prevalence (BRFSS Telephone Survey) 
 After age adjustment, 6.5% of US adults (unad-
justed prevalence, 6.8%) representing 13.7 million 
noninstitutionalized adults aged   25 years in 2011 
 Table 6— Estimated Annual Rate of Physician Ofﬁ ce Visits for COPD as the First-Listed Diagnosis Among Adults 
Aged   25 Years, by Race, Sex, and Age Group—United States, National Ambulatory Medical Care Survey, 1999-2010 
Variable 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010  P for Linear Trend
Race a,b 
 White 623.4 473.1 651.0 897.2 676.1 633.4 791.7 679.1 541.6 537.4 661.1 481.0 .585
 Black … … … … … … … … … … … … …
Sex a 
 Women 660.2 432.4 647.4 955.5 678.8 679.0 622.1 656.2 587.7 557.3 726.3 458.3 .725
 Men 572.0 519.5 583.3 714.6 701.4 547.5 789.3 688.6 515.6 410.5 525.4 554.4 .233
Age group, y
 25-44 216.2 176.3 223.0 364.8 329.5 258.9 256.8 158.5 234.2 234.0 203.8 … .082
 45-54 363.7 … … 495.5 594.3 387.3 … 409.5 323.7 228.4 488.0 … .033
 55-64 987.5 … … 960.0 614.4 843.8 799.8 1,009.1 589.7 619.7 873.5 600.7 .826
 65-74 1,603.7 1,224.9 1,417.7 2,150.8 1,586.8 1,371.6 1,820.3 1,830.4 1,670.3 953.4 1,120.6 1,505.7 .264
   75 1,464.0 1,393.7 1,867.6 2,309.7 1,636.7 1,716.1 2,102.2 1,946.0 1,257.2 1,573.2 2,189.8 1,936.1 .380
Total a 609.2 466.6 604.8 836.2 673.5 614.2 691.6 663.1 543.0 483.3 632.3 494.8 .541
Total c 596.4 456.2 594.5 824.5 668.0 614.2 689.9 674.1 545.8 490.1 654.6 516.1 .848
Annual rate per 10,000 US civilian population. COPD includes ICD-9-CM codes 490-492 or 496. Ellipses indicate unreliable estimate (relative 
SE  . 30% and/or number of records  , 30). See Table 5 legend for expansion of abbreviation.
 a Age-adjusted to the 2000 US standard population aged   25 y.
 b Data not available for other speciﬁ c race groups.
 c Unadjusted rate.
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were estimated to have a self-reported physician diag-
nosis of COPD based on a telephone survey ( Table 1 ). 
The age-adjusted prevalence displayed a strong age 
gradient, and the age-adjusted prevalence was higher 
in women (7.3%) than in men (5.7%) and higher in 
American Indian/Alaska Natives (11.0%) than in non-
Hispanic whites (6.9%), non-Hispanic blacks (6.5%), 
Hispanics (4.1%), and Asian/Paciﬁ c Islanders (2.5%). 
The age-adjusted prevalence varied between states 
( Table 2 ). The highest age-adjusted prevalence of 
COPD in 2011 was clustered in the southern states 
and along the Ohio River Valley ( Fig 1 ). 
 Prevalence (NHIS Interview Survey) 
 During the period from 1999 to 2011, the estimated 
numbers ( Table 3 ) and age-adjusted prevalence of 
COPD ( Table 4 ) ﬂ uctuated. Prevalence increased 
among successive age groups up to age 65 years and 
older, and the age-adjusted prevalence was usually 
higher among non-Hispanic whites compared with 
non-Hispanic blacks or Hispanics. The annual age-
adjusted prevalence was higher in women than in 
men ( Fig 2 ). The highest age-adjusted prevalence for 
both men and women was observed in 2001. Despite 
substantial interyear variation in age-adjusted preva-
lence estimates, signiﬁ cant tests for linear trend sug-
gested declines during 1999 to 2011 in the age-adjusted 
prevalence among all adults ( P  5 .019) and adults aged 
25 to 44 years ( P  , .001). 
 Physician Ofﬁ ce Visits (NAMCS) 
 In 2010, there were an estimated 10.3 million 
(unadjusted, 516.1 per 10,000 US civilian population; 
age-adjusted, 494.8 per 10,000 US civilian popula-
tion) physician ofﬁ ce visits with a ﬁ rst-listed diagnosis 
of COPD among adults aged   25 years. The age-
adjusted rate of ofﬁ ce visits for COPD was higher 
among men than women in 2010 ( Fig 3 ) and higher 
among whites than blacks during 2009 to 2010 ( Fig 4 ). 
There was considerable temporal variability in the 
estimated number of physician-based ofﬁ ce visits 
( Table 5 ). As expected for a chronic disease, age-speciﬁ c 
rates for ofﬁ ce visits for COPD increased substan-
tially within each given year ( Table 6 ), and age-speciﬁ c 
rates declined during 1999 to 2010 among those aged 
45 to 54 years ( P  5 .033). No clear time trend was evi-
dent for age-adjusted rates among any group deﬁ ned 
by sex or race ( Table 6 ). 
 ED Visits (NHAMCS) 
 In 2010, there were an estimated 1.5 million 
(unadjusted rate, 73.6 per 10,000 US civilian popu-
lation; age-adjusted rate, 72.0 per 10,000 US civilian 
population) ED visits with a ﬁ rst-listed diagnosis of 
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COPD among adults aged   25 years. The age-adjusted 
rate of ED visits for COPD was higher among women 
than men in 2010 ( Fig 3 ) and among blacks than 
whites during 2009 to 2010 ( Fig 4 ). The estimated 
annual number of ED visits for COPD ﬂ uctuated 
( Table 7 ). There was a considerable increase each 
year in age-speciﬁ c rates for ED visits with advancing 
age up to ages 65 years and older ( Table 8 ), but there 
were no signiﬁ cant temporal trends during 1999 to 
2010 in age-speciﬁ c and age-adjusted rates for any 
group deﬁ ned by age, race, or sex. 
 Hospitalizations (NHDS) 
 In 2010, there were an estimated 699,000 hospital-
izations (unadjusted rate, 34.4 per 10,000 US civilian 
population; age-adjusted rate, 32.2 per 10,000 US civil-
ian population) for COPD as the ﬁ rst-listed diagnosis 
among adults aged   25 years. Age-adjusted rates of 
hospitalizations for COPD varied little between men 
and women in 2010 ( Fig 3 ) or between blacks and 
whites during 2009 to 2010 ( Fig 4 ). The annual number 
of hospitalizations for COPD ﬂ uctuated between 
1999 and 2010 ( Table 9 ). The age-speciﬁ c hospital 
rates for COPD increased with advancing age each 
year ( Fig 5 ), and there was a decline in age-speciﬁ c 
rates during 1999 to 2010 among adults aged 25 to 
44 years ( P  5 .039), adults aged 55 to 64 years ( P  5 .001), 
adults aged 65 to 74 years ( P  5 .005), and adults 
aged   75 years ( P  5 .018) ( Table 10 ). Declining trends 
for age-adjusted rates for COPD hospitalization dur-
ing 1999 to 2010 were observed among all adults 
 Table 8— Estimated Annual Rate of ED Visits for COPD as the First-Listed Diagnosis Among Adults Aged   25 Years, 
by Race, Sex, and Age Group—United States, National Hospital Ambulatory Medical Care Survey, 1999-2010 
Variable 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010  P for Linear Trend
Race a,b 
 White 82.7 86.7 69.0 68.4 78.9 61.4 70.6 60.4 66.0 77.8 86.9 70.6 .541
 Black 160.8 133.0 120.8 120.0 143.4 87.7 166.9 153.2 94.4 121.1 123.4 112.6 .411
Sex a 
 Women 87.7 96.9 75.0 79.0 91.5 62.5 83.5 71.3 82.1 82.4 97.9 88.0 .769
 Men 95.2 82.4 70.4 62.4 77.0 62.5 74.3 64.9 49.1 78.4 79.3 54.5 .072
Age group, y
 25-44 54.3 58.6 58.9 50.4 45.2 43.4 60.0 38.2 48.7 44.1 55.0 48.2 .166
 45-54 75.8 52.5 49.7 46.0 72.5 36.5 51.1 68.2 58.7 62.8 67.1 64.4 .281
 55-64 116.8 133.5 78.4 85.4 92.4 63.8 88.8 80.9 65.1 95.8 84.7 80.8 .478
 65-74 130.9 150.3 114.7 121.6 175.4 139.1 109.2 134.7 122.2 161.3 188.6 135.0 .505
   75 212.9 195.2 135.8 154.6 194.9 123.0 185.8 120.4 115.8 179.2 195.5 124.5 .142
Total a 89.8 89.6 72.5 71.2 84.6 61.9 78.8 67.8 66.8 79.5 88.3 72.0 .432
Total c 88.3 88.4 71.9 70.6 84.2 61.3 78.5 68.5 66.9 81.0 89.2 73.6 .428
Annual rate per 10,000 US civilian population. COPD includes ICD-9-CM codes 490-492 or 496. All relative SEs are   30%. See Table 5 legend 
for expansion of abbreviation.
 a Age-adjusted to the 2000 US standard population aged   25 y.
 b Data not available for other speciﬁ c race groups.
 c Unadjusted rate.
 Table 9— Estimated Annual Number of Hospitalizations for COPD as the First-Listed Discharge Diagnosis Among 
Adults Aged   25 Years, by Race, Sex, and Age Group—United States, National Hospital Discharge Survey, 1999-2010 
Variable 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Race a 
 White 500,000 441,000 457,000 462,000 460,000 429,000 505,000 452,000 440,000 493,000 573,000 543,000
 Black 59,000 47,000 54,000 53,000 49,000 45,000 50,000 55,000 52,000 59,000 62,000 80,000
Sex
 Women 402,000 350,000 362,000 368,000 369,000 336,000 387,000 344,000 345,000 414,000 416,000 398,000
 Men 300,000 297,000 288,000 293,000 304,000 291,000 324,000 312,000 294,000 296,000 312,000 301,000
Age group, y
 25-44 28,000 28,000 21,000 27,000 24,000 19,000 21,000 23,000 25,000 20,000 18,000 17,000
 45-54 59,000 64,000 62,000 66,000 70,000 72,000 81,000 72,000 75,000 75,000 86,000 81,000
 55-64 134,000 129,000 115,000 132,000 128,000 123,000 145,000 133,000 126,000 138,000 150,000 145,000
 65-74 219,000 188,000 190,000 200,000 189,000 173,000 193,000 183,000 179,000 193,000 211,000 205,000
   75 261,000 239,000 263,000 236,000 263,000 241,000 271,000 245,000 234,000 284,000 262,000 251,000
Total 702,000 647,000 650,000 662,000 673,000 628,000 711,000 657,000 639,000 710,000 728,000 699,000
Numbers for each variable may not add to total because of rounding. COPD includes ICD-9-CM codes 490-492 or 496. See Table 5 legend for 
expansion of abbreviation.
 a Data not available for other speciﬁ c race groups. Race was not imputed. Percent missing data for race are shown in e-Table 5.
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( P  5 .001), men ( P  , .001), and women ( P  5 .022) 
( Table 10 ). 
 Medicare Hospitalizations (Medicare 
Part A Hospital Claims) 
 In 2010, there were 312,654 (unadjusted rate, 11.11 
per 1,000 Medicare enrollees aged   65 years; age-
adjusted rate, 11.18 per 1,000 Medicare enrollees 
aged   65 years) hospital discharge claims for COPD 
as the ﬁ rst-listed diagnosis. The annual number of 
Medicare hospitalizations for COPD ﬂ uctuated during 
1999 to 2010 ( Table 11 ). Age-speciﬁ c rates for those 
aged 65 to 74 years declined signiﬁ cantly ( P  5 .033) 
( Table 12 ). Age-adjusted rates were highest among 
Native American enrollees and lowest among Asian 
enrollees in most years ( Fig 6 ). Age-adjusted rates for 
Medicare hospitalizations for COPD declined during 
1999 to 2010 for all enrollees overall ( P  5 .045) and 
men ( P  5 .022), but the decline was not signiﬁ cant for 
women ( P  5 .138) or for speciﬁ c race groups ( Table 12 ). 
 Medicare hospital claims data provide an oppor-
tunity to obtain state-speciﬁ c estimates ( Table 13 ). 
Changes in age-adjusted rates during 1999 to 2010 
varied between states ( Table 14 ). A comparison of 
state-speciﬁ c Medicare hospital rates in 1999 to 2000 
 Figure 5. Age-speciﬁ c rates (per 10,000 US civilian population) of hospitalizations for COPD as the 
ﬁ rst-listed discharge diagnosis among adults aged   25 years, by year—United States, National Hospital 
Discharge Survey, 1999-2010. 
 Table 10— Estimated Annual Rates of Hospitalizations for COPD as the First-Listed Discharge Diagnosis Among 
Adults Aged   25 Years, by Race, Sex, and Age Group—United States, National Hospital Discharge Survey, 1999-2010 
Variable 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010  P for Linear Trend
Race a,b 
 White 32.7 28.5 28.5 28.6 28.0 25.8 29.8 26.3 25.3 27.6 31.6 29.5 .104
 Black 37.6 29.2 29.2 30.4 28.5 24.9 26.9 29.9 26.2 28.8 30.2 39.5 .563
Sex a 
 Women 40.8 35.3 35.3 35.3 34.5 31.1 35.2 30.9 30.4 35.6 35.3 33.4 .022
 Men 39.9 39.0 39.0 36.7 37.4 35.3 38.4 36.4 33.1 32.9 33.9 31.6  , .001
Age group, y
 25-44 3.3 3.3 2.4 3.2 2.9 2.3 2.5 2.8 3.0 2.4 2.2 2.1 .039
 45-54 16.5 17.3 15.9 16.5 17.1 17.2 19.0 16.7 17.1 16.9 19.4 18.4 .102
 55-64 57.9 54.0 45.5 49.7 45.8 42.3 47.8 42.1 38.6 41.0 43.1 40.2 .001
 65-74 121.6 104.7 103.6 109.7 103.0 93.9 103.7 96.8 92.7 96.0 101.5 95.5 .005
   75 161.3 144.8 154.7 136.1 149.7 135.0 149.1 133.7 126.2 151.4 139.8 131.4 .018
Total a 40.2 36.6 36.6 35.5 35.5 32.5 36.1 32.8 31.4 34.1 34.3 32.2 .001
Total c 39.7 36.2 35.4 35.5 35.8 33.0 36.8 33.6 32.4 35.6 36.2 34.4 .018
Annual rate per 10,000 US civilian population. COPD includes ICD-9-CM codes 490-492 or 496. All relative SEs are   30%. See Table 5 legend 
for expansion of abbreviation.
 a Age-adjusted to the 2000 US standard population aged   25 y.
 b Data not available for other speciﬁ c race groups. Race was not imputed. Percent missing data for race are shown in e-Table 5.
 c Unadjusted rate.
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to those in 2009 to 2010 ( Fig 7 ) demonstrates geo-
graphic clustering of the 10 states in 1999 to 2000, 
with the highest hospitalization rates (14.0-26.6 per 
1,000 Medicare enrollees) along the Mississippi River 
and Ohio River valleys. By 2009 to 2010, there was a 
marked improvement in rates in many of those states. 
States with the highest age-adjusted Medicare hospi-
talization rates in 2009 to 2010 in  Figure 7 are similar 
to those states in  Figure 1, with the highest age-
adjusted prevalence of COPD in 2011.  Figure 8 shows 
that there were no signiﬁ cant increases in age-adjusted 
Medicare hospitalization rates in any state during 
1999 to 2010 and identiﬁ es those states which have 
experienced no signiﬁ cant change or a signiﬁ cant 
decline ( P  , .05) during the past decade. 
 Deaths (Death Certiﬁ cates) 
 In 2010, there were 133,575 deaths (crude rate, 65.5 
per 100,000 US population; age-adjusted rate, 63.1 per 
100,000 population) among adults aged   25 years. 
Although the annual number of deaths increased some-
what during 1999 to 2010 ( Table 15 ), the age-adjusted 
death rate for COPD declined during 1999 to 2010 
among men ( P  5 .001) but did not change signiﬁ cantly 
in women ( P  5 .127) or overall ( P  5 .163) ( Table 16 ). 
 Table 11— Annual Number of Medicare Hospitalizations for COPD as the First-Listed Discharge Diagnosis Among 
Medicare Beneﬁ ciaries Aged   65 Years, by Race/Ethnicity, Sex, and Age Group—United States, Medicare Part A 
Hospital Claims, 1999-2010 
Variable 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Race/ethnicity
 White, 
 non-Hispanic
311,551 282,944 286,225 288,338 280,631 255,896 277,529 266,810 234,796 277,693 265,149 273,918
 Black, 
 non-Hispanic
25,468 23,545 24,280 25,530 24,313 22,003 24,312 22,740 21,344 23,893 24,611 27,106
 Hispanic 4,422 4,030 4,256 4,347 4,183 3,945 4,505 4,196 3,892 4,531 4,517 4,770
 Native American 581 519 577 1,018 1,210 1,229 1,228 1,553 1,176 1,468 1,432 1,547
 Asian 1,818 1,553 1,683 1,772 1,750 2,865 1,901 1,719 1,879 2,327 2,369 2,442
Sex
 Women 194,756 177,658 179,941 181,588 176,902 162,180 174,986 167,743 149,181 174,940 168,625 175,597
 Men 154,141 139,843 141,875 143,795 139,164 126,169 138,283 132,445 116,711 138,212 132,266 137,057
Age group, y
 65-74 152,179 136,721 138,118 137,777 136,354 122,701 131,321 125,471 111,455 130,057 128,891 134,072
   75 196,718 180,780 183,698 187,606 179,802 165,648 181,948 174,717 154,437 183,095 172,000 178,582
Total 348,897 317,501 321,816 325,383 316,156 288,349 313,269 300,188 265,892 313,152 300891 312,654
COPD includes ICD-9-CM codes 490-492 or 496. See Table 5 legend for expansion of abbreviation.
 Table 12— Annual Rates of Medicare Hospitalizations for COPD Among Medicare Beneﬁ ciaries Aged   65 Years, by 
Race/Ethnicity, Sex, and Age Group—United States, Medicare Part A Hospital Claims, 1999-2010 
Variable 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010  P for Linear Trend
Race a 
 White, 
 non-Hispanic
13.47 12.00 11.80 11.58 11.09 10.02 10.86 10.73 9.61 11.50 11.03 11.31 .052
 Black, 
 non-Hispanic
12.59 11.29 11.19 11.42 10.63 9.48 10.49 10.29 9.98 11.37 11.55 12.39 .831
 Hispanic 13.39 10.89 10.68 10.24 9.30 8.12 9.09 8.77 8.14 9.66 9.44 9.73 .081
 Native American 19.21 14.65 15.62 11.80 13.14 12.73 11.61 14.84 10.88 13.32 12.62 13.23 .394
 Asian 8.42 5.50 5.42 5.20 4.75 6.96 4.36 3.92 4.11 4.91 4.81 4.77 .108
Sex a 
 Women 12.41 11.22 11.08 10.90 10.50 9.52 10.28 10.17 9.22 10.97 10.64 10.99 .138
 Men 14.81 13.14 12.83 12.53 11.81 10.54 11.47 11.23 9.99 11.91 11.34 11.56 .022
Age group, y
 65-74 11.26 10.01 9.81 9.51 9.24 8.19 8.75 8.58 7.70 8.90 8.72 8.88 .033
   75 15.49 13.98 13.79 13.67 12.87 11.72 12.86 12.69 11.47 13.94 13.24 13.69 .175
Total a 13.28 11.91 11.71 11.49 10.97 9.88 10.71 10.55 9.50 11.31 10.87 11.18 .045
Total b 13.31 11.94 11.74 11.53 11.00 9.91 10.74 10.58 9.51 11.29 10.83 11.11 .034
Annual rate per 1,000 Medicare beneﬁ ciaries, aged   65 y, alive, entitled to Medicare Part A, and not in a managed care plan on July 1 of the given 
year. COPD includes ICD-9-CM codes 490-492 or 496. See Table 5 legend for expansion of abbreviation.
 a Age-adjusted to the 2000 US standard population aged   65 y.
 b Unadjusted rate.
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 Discussion 
 The previous COPD surveillance report noted that 
rates of hospitalizations and mortality for COPD had 
increased from 1980 to 2000. 13 However, the mor-
tality rate in men and some age groups and hospitali-
zation rates in both men and women have declined 
since 1999. Rates of physician-based ofﬁ ce visits and 
ED visits for COPD from 1999 to 2010 demonstrated 
substantial interyear variability and showed no par-
ticular trend; however, it is encouraging that there 
were no increases in ofﬁ ce visit rates or ED rates for 
COPD. 
 Because smoking is the most important etiologic 
driver of COPD, 22 trends in the prevalence of smoking 
impacted many of the metrics examined in this sur-
veillance report, although the exact temporal rela-
tionship between changes in the smoking prevalence 
and changes in health-care use and mortality for COPD 
are not well deﬁ ned. Since 1965, the prevalence of 
smoking has decreased considerably. In 1965, 42.4% 
(unadjusted percentage) of adults aged   18 years 
were current smokers compared with 19.3% in 2010. 23 
The crude prevalence of smoking in 2010 was one-
half that in 1965 for both men (21.5% vs 51.9%, respec-
tively) and women (17.3% vs 33.9%, respectively). In 
1999 to 2001, American Indian/Alaska Native adults 
had a higher age-adjusted prevalence of current smok-
ing (30.3% in men and 34.7% in women) compared with 
white adults (25.1% in men and 22.2% in women), 23 
which may explain the increase in COPD mortality 
Age-speciﬁ c rates increased among adults aged 45 to 
54 years ( P  , .001) but declined among those aged 
55 to 64 years ( P  5 .002) and 65 to 74 years ( P  , .001). 
The age-speciﬁ c rates each year were highest among 
those aged   75 years and 65 to 74 years ( Fig 9 ). 
Age-adjusted rates were highest among non-Hispanic 
whites followed by American Indian/Alaska Natives, 
non-Hispanic blacks, Hispanics, and Asian/Pacific 
Islanders ( Fig 10 ). During 1999 to 2010, age-adjusted 
rates increased among American Indian/Alaska Natives 
( P  5 .008) and declined among Hispanics ( P  5 .038) 
and Asian/Pacific Islanders ( P  , .001) but did not 
change signiﬁ cantly among non-Hispanic whites or 
non-Hispanic blacks. 
 Numbers of deaths ( Table 17 ) and age-adjusted 
death rates varied during 1999 to 2010 in most states 
( Table 18 ).  Figure 11 compares aggregated age-adjusted 
state-speciﬁ c death rates for COPD in 1999 to 2000 
to those for 2009 to 2010. In 1999 to 2000, states with 
the highest death rates (75.0-103.9 per 100,000) were 
along the Ohio River valley and in multiple western 
states. Geographic clustering of COPD death rates 
aggregated for 2009 to 2010 was observed in states 
along the Ohio River Valley and in several western 
states and also in several southern states ( Fig 11 ). 
Although death rates for COPD declined in many 
states during 1999 to 2010, ﬁ ve states (Alabama, 
Mississippi, Arkansas, Oklahoma, and South Dakota) 
experienced signiﬁ cant increases in deaths from COPD 
( Fig 12 ). 
 Figure 6. Race-speciﬁ c age-adjusted rates (per 1,000 Medicare enrollees) of Medicare hospitali-
zations for COPD as the ﬁ rst-listed discharge diagnosis among Medicare enrollees aged   65 years, by 
year—United States, Medicare Part A hospital claims, 1999-2010. 
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decline in mortality from COPD may be expected for 
that population in the future. However, a recent report 
observed that almost 39% of 15 million adults with 
self-reported COPD in 2011 in the United States 
during 1999 to 2010 in that population. The prevalence 
of current smoking among American Indian/Alaska 
Native adults has since declined to 25.1% in men and 
21.0% in women for 2008 to 2010 23 ; therefore, a 
 Table 13— Annual Number of Medicare Hospitalizations for COPD as the First-Listed Discharge Diagnosis Among 
Medicare Beneﬁ ciaries Aged   65 Years, by State—United States, Medicare Part A Hospital Claims, 1999-2010 
State 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Alabama 8,996 8,172 8,751 8,779 8,442 7,216 7,842 7,098 6,805 8,132 7,686 7,704
Alaska 391 404 414 378 387 341 320 408 290 355 335 373
Arizona 3,317 2,890 2,914 3,152 3,101 3,006 3,638 2,967 2,652 3,543 3,482 4,082
Arkansas 5,444 5,033 4,991 5,202 4,798 4,148 4,563 4,598 3,651 3,957 3,858 3,956
California 20,181 17,174 17,142 17,382 17,045 14,601 15,331 14,392 14,367 17,093 17,302 18,743
Colorado 2,830 2,264 2,332 2,317 2,350 2,013 2,337 2,406 1,954 2,535 2,117 2,397
Connecticut 3,032 2,964 3,125 3,315 3,276 3,227 3,487 3,359 3,300 3,886 3,698 3,768
Delaware 983 1,038 992 1,028 1,047 1,088 1,188 1,052 1,069 1,105 1,066 1,257
District of 
Columbia
463 458 443 418 391 343 438 363 336 445 404 451
Florida 23,513 21,200 22,448 23,194 22,096 22,210 22,732 21,121 19,590 23,592 23,926 24,952
Georgia 9,983 9,269 9,434 9,591 9,089 8,215 9,146 9,092 7,491 8,617 8,660 8,517
Hawaii 470 412 421 406 379 377 386 369 373 424 410 424
Idaho 1,249 1,001 994 930 852 659 729 884 567 609 616 603
Illinois 16,794 14,861 15,180 15,556 14,669 13,354 14,618 14,566 13,146 16,660 16,089 16,021
Indiana 10,357 9,831 9,774 9,551 9,109 8,178 9,334 9,334 7,543 9,624 8,835 8,682
Iowa 5,008 4,308 4,234 3,734 3,369 2,977 2,940 3,736 2,424 2,774 2,546 2,645
Kansas 3,822 3,321 3,247 3,205 3,282 2,759 3,066 3,542 2,440 2,749 2,450 2,441
Kentucky 10,655 9,496 9,959 9,839 9,730 8,546 9,544 9,752 7,731 9,423 9,188 8,986
Louisiana 6,520 6,031 6,373 6,418 6,228 5,258 5,887 5,155 4,490 5,389 5,150 5,287
Maine 2,380 2,477 2,056 1,863 1,837 1,635 1,761 1,938 1,438 1,625 1,712 1,588
Maryland 5,437 5,283 5,631 5,746 5,695 5,211 5,898 6,221 6,223 7,086 6,470 6,522
Massachusetts 7,890 7,447 7,117 7,053 7,170 6,754 7,277 7,108 6,828 8,437 8,185 8,689
Michigan 14,207 12,606 12,377 13,285 12,984 12,892 13,915 13,152 11,491 13,053 12,627 14,282
Minnesota 4,764 4,130 4,291 4,061 3,745 3,560 3,667 3,354 2,513 3,097 2,862 2,930
Mississippi 6,361 6,017 6,191 6,117 5,851 5,128 5,666 5,090 4,164 4,858 5,005 4,983
Missouri 8,527 7,535 8,037 7,709 7,455 7,023 7,909 7,254 6,082 7,451 6,884 6,932
Montana 1,306 1,142 1,203 1,072 1,015 874 867 1,100 704 759 718 717
Nebraska 2,108 1,713 1,542 1,452 1,443 1,208 1,590 1,981 1,337 1,693 1,516 1,705
Nevada 1,969 1,551 1,488 1,576 1,529 1,332 1,544 1,547 1,346 1,754 1,890 2,062
New 
Hampshire
1,329 1,450 1,361 1,305 1,335 1,452 1,318 1,640 1,358 1,626 1,541 1,499
New Jersey 10,193 9,420 9,584 10,325 10,742 10,172 11,049 10,265 9,882 11,328 10,836 11,166
New Mexico 1,569 1,309 1,342 1,400 1,356 1,138 1,430 1,214 1,116 1,348 1,316 1,418
New York 20,526 18,680 17,835 17,878 17,360 16,983 18,046 17,177 15,787 17,987 17,643 19,369
North Carolina 12,146 11,326 11,079 10,940 11,079 9,511 10,610 9,911 8,819 10,097 9,655 9,530
North Dakota 970 770 742 633 576 548 631 838 553 495 393 410
Ohio 18,466 16,823 17,282 17,601 17,255 15,239 16,863 16,229 14,217 16,242 14,712 15,278
Oklahoma 5,558 5,057 5,456 5,392 5,256 4,779 5,186 5,055 4,973 5,587 5,227 5,574
Oregon 2,329 1,925 2,073 2,201 2,029 1,672 1,646 1,768 1,354 1,469 1,544 1,551
Pennsylvania 19,100 17,406 16,841 17,294 16,401 15,426 16,677 14,169 12,866 14,900 13,724 15,694
Rhode Island 1,178 1,167 1,063 1,014 1,054 954 1,021 972 969 1,140 1,115 1,288
South Carolina 5,427 5,104 5,054 5,327 5,277 4,815 5,333 4,689 4,444 5,153 4,910 5,002
South Dakota 1,219 1,052 938 890 860 649 751 1,104 534 653 668 605
Tennessee 10,251 9,771 9,989 10,025 10,101 9,285 9,799 9,102 8,215 10,032 9,587 9,188
Texas 21,794 20,395 22,665 23,830 23,043 20,590 22,387 20,379 19,180 22,262 21,264 22,557
Utah 750 623 718 692 645 521 628 547 425 528 498 551
Vermont 719 774 632 629 601 618 568 615 458 499 549 548
Virginia 9,254 8,672 8,793 8,712 8,561 7,331 8,008 7,356 6,865 8,030 7,579 7,306
Washington 3,660 3,303 3,459 3,403 3,180 2,852 3,516 3,562 2,925 3,516 3,478 3,540
West Virginia 6,678 6,295 5,889 5,880 5,830 4,979 5,249 5,541 4,474 4,859 4,611 4,706
Wisconsin 6,064 5,573 5,353 5,143 4,747 4,290 4,441 4,548 3,639 4,088 3,828 3,735
Wyoming 760 578 567 540 504 412 492 568 494 588 526 440
Total 348,897 317,501 321,816 288,338 316,156 288,349 313,269 300,188 265,892 313,152 300,891 312,654
COPD includes ICD-9-CM codes 490-492 or 496. See Table 5 legend for expansion of abbreviation.
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 Table 14— Age-Adjusted Annual Rates for Medicare Hospitalizations With COPD as the First-Listed Discharge 
Diagnosis Among Medicare Beneﬁ ciaries Aged   65 Years, by State—United States, Medicare Part A Hospital Claims, 
1999-2010 
State a 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010  P for Linear Trend
Alabama 18.10 16.42 17.33 17.04 16.17 13.84 15.11 13.99 13.56 16.73 16.15 15.68 .121
Alaska 12.62 12.31 12.26 10.89 10.60 9.05 8.01 9.85 6.59 7.76 6.88 7.49  , .001
Arizona 9.88 7.97 7.61 7.63 7.14 6.64 7.83 6.89 6.05 8.01 7.66 8.62 .541
Arkansas 16.14 14.84 14.70 14.67 13.44 11.53 12.54 13.02 10.70 11.67 11.36 11.53  , .001
California 11.33 9.44 9.06 8.51 7.98 6.71 6.95 6.56 6.49 7.57 7.54 8.04 .027
Colorado 11.93 9.22 8.96 8.35 8.17 6.79 7.71 8.01 6.44 8.27 6.80 7.49 .015
Connecticut 8.52 8.21 8.02 7.70 7.56 7.41 8.01 7.81 7.90 9.55 9.30 9.48 .057
Delaware 10.97 11.34 10.48 10.52 10.44 10.61 11.33 9.87 9.89 10.06 9.53 10.79 .060
District of 
Columbia
8.17 8.00 7.60 7.21 6.87 6.11 7.89 6.66 6.22 8.33 7.41 8.08 .736
Florida 13.32 11.69 11.77 11.52 10.65 10.57 10.88 10.58 9.88 12.02 12.15 12.55 .747
Georgia 14.76 13.50 13.29 13.28 12.35 10.70 11.67 11.98 10.00 11.25 11.25 11.63 .004
Hawaii 5.18 4.34 4.50 4.29 3.92 3.80 3.81 3.72 3.70 4.17 4.05 4.22 .078
Idaho 9.87 7.81 7.57 6.93 6.23 4.72 5.13 6.50 4.28 4.65 4.78 4.62  , .001
Illinois 13.49 11.91 11.91 11.72 10.89 9.88 10.79 10.94 9.95 12.53 11.94 11.71 .439
Indiana 14.92 14.09 13.85 13.38 12.57 11.21 12.73 13.09 10.88 14.05 13.11 12.83 .202
Iowa 12.18 10.46 10.28 9.04 8.16 7.26 7.24 9.54 6.31 7.18 6.65 6.91  , .001
Kansas 11.95 10.41 10.21 9.91 9.93 8.29 9.21 10.81 7.53 8.54 7.67 7.57 .001
Kentucky 23.83 21.10 21.76 21.07 20.58 17.87 19.67 20.45 16.93 20.80 20.34 19.77 .080
Louisiana 16.95 15.23 15.38 15.02 14.35 12.03 13.93 12.43 11.12 13.62 13.23 13.52 .015
Maine 13.60 14.05 11.48 10.28 10.05 8.83 9.44 10.31 7.65 8.75 9.67 9.03 .005
Maryland 11.52 10.63 10.26 10.35 10.17 9.23 10.36 11.10 11.06 12.40 10.91 10.80 .338
Massachusetts 13.15 12.28 11.53 11.28 10.85 10.14 10.95 10.66 10.31 12.72 12.30 12.93 .908
Michigan 12.71 11.24 11.00 11.32 10.93 10.74 11.53 11.24 10.99 13.38 13.43 13.05 .139
Minnesota 9.83 8.41 8.60 8.08 7.42 7.08 7.46 7.62 5.97 7.69 7.37 8.10 .036
Mississippi 19.86 18.74 19.27 18.73 17.72 15.34 16.89 16.06 13.05 15.16 15.51 15.19  , .001
Missouri 13.92 12.41 13.12 12.53 11.82 11.05 12.40 11.52 9.76 12.06 11.24 11.31 .014
Montana 11.44 9.73 10.13 8.95 8.36 7.10 6.98 9.27 6.10 6.63 6.34 6.26  , .001
Nebraska 9.92 7.90 7.11 6.66 6.64 5.54 7.32 9.32 6.38 8.14 7.26 8.09 .882
Nevada 15.60 11.66 10.85 10.78 9.79 8.31 9.31 9.20 7.83 9.83 10.37 10.85 .177
New 
Hampshire
10.37 10.12 9.35 8.84 8.83 9.41 8.40 10.25 8.42 10.01 9.48 9.08 .504
New Jersey 11.69 10.45 10.42 10.73 11.02 10.40 11.34 10.56 10.11 11.55 11.13 11.36 .576
New Mexico 10.62 8.60 8.26 8.52 8.10 6.73 8.29 7.24 6.59 7.89 7.68 8.09 .071
New York 11.64 10.52 9.94 9.92 9.64 9.09 9.79 9.62 9.05 10.52 10.46 11.56 .933
North 
Carolina
13.92 12.78 12.33 12.02 11.91 10.11 11.22 10.76 9.75 11.07 10.49 10.08  , .001
North Dakota 10.51 8.34 8.04 6.91 6.27 5.98 6.88 9.44 6.31 5.72 4.53 4.71 .003
Ohio 15.65 14.13 14.11 14.24 13.77 12.06 13.36 13.13 11.71 14.78 13.59 15.60 .494
Oklahoma 14.40 13.13 14.07 13.60 13.09 11.83 12.79 12.95 12.46 14.01 13.03 13.77 .524
Oregon 9.23 7.52 7.83 8.11 7.33 5.89 5.72 6.38 4.99 5.34 5.67 5.52  , .001
Pennsylvania 14.25 13.18 12.16 12.41 11.86 11.21 12.28 11.15 10.46 12.82 12.00 13.65 .289
Rhode Island 12.72 12.46 11.56 10.93 11.66 10.60 11.63 11.13 11.26 13.29 13.03 14.62 .223
South 
Carolina
12.28 11.30 10.98 11.38 11.06 9.88 10.73 9.62 9.24 10.73 10.11 10.04 .008
South Dakota 11.49 9.86 8.81 8.39 7.92 5.94 6.84 10.06 5.04 6.28 6.19 5.55 .004
Tennessee 16.34 15.49 15.54 15.68 15.75 14.43 15.28 14.82 13.66 16.73 15.82 15.12 .442
Texas 13.94 12.81 13.11 13.11 12.29 10.82 11.68 10.79 10.23 11.87 11.23 11.69 .009
Utah 4.44 3.60 4.07 3.85 3.50 2.76 3.31 3.22 2.61 3.37 3.29 3.62 .073
Vermont 9.92 10.33 8.37 8.24 7.79 7.89 7.18 7.62 5.65 6.08 6.61 6.48  , .001
Virginia 13.44 12.15 11.90 11.62 11.20 9.44 10.13 9.54 8.98 10.47 9.82 9.27  , .001
Washington 8.19 7.13 6.96 6.51 5.93 5.14 6.19 6.26 5.16 6.20 6.13 6.09 .065
West Virginia 27.38 25.81 24.10 23.95 23.62 20.11 21.06 22.62 21.20 23.50 22.52 22.50 .033
Wisconsin 9.32 8.56 8.16 7.60 7.04 6.43 6.84 7.54 6.35 7.41 7.20 7.12 .022
Wyoming 14.19 10.65 10.22 9.67 8.83 7.12 8.31 9.66 8.28 9.72 8.58 7.02 .023
Total a 13.28 11.91 11.71 11.49 10.97 9.88 10.71 10.55 9.50 11.31 10.87 11.18 .045
Annual rate per 1,000 Medicare enrollees aged   65 y, alive, entitled to Medicare Part A, and not in a managed care plan on July 1 of the given year. 
COPD includes ICD-9-CM codes 490-492 or 496. See Table 5 legend for expansion of abbreviation.
 a Age-adjusted to the 2000 US standard population aged   65 y.
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with COPD, mortality rates can be expected to decline 
in future years. 
 The generally small reduction in the age-adjusted 
mortality rate was limited to men. It is unclear why 
the mortality rate in women did not fall as well, given 
the decline in smoking prevalence in women since 
1965. If the estimates are valid, these results suggest 
that research will be needed to address possible expla-
nations for the poor progress among women. These 
data are consistent with the results of a study show-
ing that the mortality rate among women with an 
obstructive impairment changed little in contrast to 
the mortality rate among men with an obstructive 
impairment. 26 
 The use of spirometry is critical to establishing the 
diagnosis and severity of COPD. Additional tests that 
can help in the diagnosis include lung diffusion capac-
ity test, chest radiograph, and arterial blood gas test. 
GOLD (Global Initiative for Chronic Obstructive 
Lung Disease) established four levels of COPD on 
the basis of spirometric measurements: mild, mod-
erate, severe, and very severe. 27 The results reported 
here should be considered in the context of several 
limitations. Depending on the spirometric criteria 
used, estimates of prevalence of COPD based on 
spirometry tests may be as much as double the esti-
mates derived from self-reported information. 13,28,29 
Consequently, the estimates of self-reported prevalence 
of COPD in the current surveillance report almost 
certainly underestimate the true prevalence of this 
condition. Furthermore, not accounting for the undi-
agnosed percentage of adults with COPD can also 
potentially distort demographic comparisons. As shown 
in the previous surveillance report, men had a higher 
prevalence than women when the presence of COPD 
was based on spirometric criteria. 13 When self-reported 
data were used to estimate the prevalence of COPD, 
however, women had a higher prevalence than men, 
as was also observed in the present report. 
 If COPD is underdiagnosed, then the mortality rates 
presented in the present report likely underestimate 
continued to smoke. 12 This large population repre-
sents an important opportunity for physician coun-
seling and referral to smoking cessation interventions 
such as 1-800-QUIT-NOW. 
 Two broad currents inﬂ uence mortality rates esti-
mated from death certiﬁ cate data: changes in the prev-
alence of COPD and changes in the case-fatality rate 
among people with COPD. Although the estimates 
of the prevalence of self-reported COPD from the 
NHIS suggest that the prevalence may have declined 
since 1999, the rates since 2002 have remained fairly 
stable. A number of treatment strategies have been 
shown to have the potential to reduce mortality in 
patients with COPD and include newer medications 
and evolving guidelines to treat COPD, oxygen therapy, 
respiratory management, pulmonary rehabilitation, 
and inﬂ uenza vaccinations. 24,25 The lag times between 
changes in the prevalence of COPD and the uptake 
of treatments and COPD mortality rates may differ. 
The balance of these temporal changes is likely to 
have a substantial impact on the trajectory of the 
mortality rate. With continued declines in the smoking 
prevalence and improved management of patients 
 Figure 7. Age-adjusted rates (per 1,000 Medicare enrollees) of Medicare hospitalizations for COPD as 
the ﬁ rst-listed discharge diagnosis among Medicare enrollees aged   65 years—United States, Medicare 
Part A hospital claims, 1999-2000 and 2009-2010. 
 Figure 8. Signiﬁ cant linear change ( P  , .05) in state-speciﬁ c age-
adjusted rates (per 1,000 Medicare enrollees) of Medicare hospi-
talizations for COPD as the ﬁ rst-listed discharge diagnosis among 
Medicare enrollees aged   65 years—United States, Medicare 
Part A hospital claims, 1999-2010. 
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approximately constant during the study period, the 
interpretation of the direction of the trends is valid. 
 Race was self-reported by participants of the BRFSS 
and NHIS but was recorded by medical or other per-
sonnel in the other data systems. The comparability 
of race designations among surveys is unknown. For 
the true mortality rates from COPD. 30-32 Another factor 
that may contribute to underestimating COPD mor-
tality rates is the possibility that comorbidities may 
displace COPD as the underlying cause of death that 
is reported on the death certiﬁ cate. 33 Assuming that 
underestimates of the COPD mortality rates were 
 Table 15— Annual Number of Adults Aged   25 Years With COPD as the Underlying Cause of Death, by Race, Sex, 
and Age Group—United States, Mortality Component of the National Vital Statistics System, 1999-2010 
Variable 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Race/ethnicity a 
 White, 
 non-Hispanic
107,706 106,198 107,145 108,481 110,088 106,393 113,939 108,435 111,477 123,171 119,715 119,894
 Black, 
 non-Hispanic
6,640 6,327 6,355 6,585 6,565 6,274 7,086 6,660 6,896 7,743 7,489 7,700
 Hispanic 2,488 2,341 2,512 2,724 2,827 2,779 3,166 2,994 3,238 3,623 3,672 3,817
 AIAN 360 381 378 413 455 457 467 468 559 579 555 643
 API 923 925 985 969 1,037 1,013 1,136 1,144 1,146 1,288 1,265 1,265
Sex
 Women 58,040 58,436 59,789 60,673 62,363 60,194 65,193 62,290 63,813 71,031 69,334 69,797
 Men 60,416 58,058 57,908 58,807 58,904 56,940 60,812 57,633 59,678 65,606 63,583 63,778
Age group, y
 25-44 494 500 554 586 573 554 558 519 521 566 506 453
 45-54 2,472 2,618 2,695 2,842 2,883 2,920 3,356 3,326 3,596 3869 4,083 3,861
 55-64 10,643 10,130 10,545 10,670 11,451 11,183 12,173 11,823 12,273 13518 13,636 13,674
 65-74 31,699 30,249 29,942 29,040 29,241 27,740 29,296 27,640 28,100 31390 30,762 31,254
   75 73,148 72,997 73,961 76,342 77,119 74,737 80,622 76,615 79,001 87,294 83,930 84,333
Total 118,456 116,494 117,697 119,480 121,267 117,134 126,005 119,923 123,491 136,637 132,917 133,575
COPD includes ICD-10 codes J40–J44 from the WHO. AIAN  5 non-Hispanic American Indian/Alaska Natives; API  5 non-Hispanic Asian/Paciﬁ c 
Islanders; ICD-10  5 International Classiﬁ cation of Diseases, tenth revision; WHO  5 World Health Organization.
 a A summation of the annual numbers will not equal the total annual number because of small numbers of death in other race/ethnicity or unknown 
categories.
 Table 16— Annual Rates for Deaths With COPD as the Underlying Cause Of Death Among Adults Aged   25 Years, by 
Race, Sex, and Age Group—United States, Mortality Component of the National Vital Statistics System, 1999-2010 
Variable 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010  P for Linear Trend
Race/ethnicity a 
 White, 
 non-Hispanic
72.0 70.5 70.4 70.5 70.7 67.7 71.5 67.2 68.1 74.1 71.0 70.2 .870
 Black, 
 non-Hispanic
45.9 43.0 42.6 43.6 42.5 39.8 43.8 40.3 40.8 44.6 41.7 41.8 .240
 Hispanic 32.9 29.7 29.7 30.8 30.5 28.2 30.4 27.4 28.1 29.8 28.8 28.5 .038
 AIAN 54.2 53.0 51.6 54.1 57.3 55.0 54.7 53.2 60.8 59.3 56.1 62.9 .008
 API 25.7 24.8 24.2 22.2 22.7 21.2 22.1 21.0 19.8 21.0 19.7 19.0  , .001
Sex d 
 Women 54.6 54.4 54.9 55.0 55.9 53.3 56.8 53.6 54.0 59.1 56.8 56.3 .127
 Men 88.2 83.8 81.8 81.7 79.9 75.7 78.8 73.0 73.7 79.2 74.8 73.6 .001
Age group, y
 25-44 0.6 0.6 0.7 0.7 0.7 0.7 0.7 0.6 0.6 0.7 0.6 0.6 …
 45-54 6.8 6.9 6.8 7.1 7.1 7.0 7.9 7.7 8.2 8.7 9.1 8.6  , .001
 55-64 44.8 41.7 42.0 40.0 40.9 38.2 39.7 37.0 37.0 39.6 38.5 37.5 .002
 65-74 172.1 164.5 162.9 157.9 158.1 148.6 155.2 143.9 142.6 153.1 144.9 143.9  , .001
   75 446.6 439.7 437.5 445.6 444.2 426.2 453.7 426.6 435.8 477.7 456.4 454.5 .212
Total a 67.0 65.2 64.9 65.0 64.9 61.8 65.3 61.1 61.7 66.9 63.8 63.1 .163
Total b 65.7 64.0 63.9 64.2 64.5 61.6 65.4 61.5 62.6 68.4 65.8 65.5 .515
Annual rate per 100,000 US population. COPD includes ICD-10 codes J40–J44 from the WHO. Death rates for 2001-2009 will differ from previous 
reports because 2001-2009 population denominators have been revised In CDC Wonder (Oct 2012). See Table 15 legend for expansion of 
abbreviations.
 a Age-adjusted to the 2000 US standard population aged   25 y.
 b Unadjusted rate.
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preting racial- and ethnic-speciﬁ c disparities. In the 
future, the BRFSS, with its large annual sample size 
of almost one-half million respondents, will allow trend 
analyses of prevalence of self-reported COPD among 
those racial/ethnic groups. 
 Since 1997, GOLD has striven to increase aware-
ness of COPD as a major public health problem across 
the globe, to spur efforts to prevent this disease, and 
to develop guidelines to improve the diagnosis and 
treatment of COPD. In 2013, it released updated 
some data systems, such as the NAMCS, NHAMCS, 
and NHDS, race was missing for a large proportion 
of records. For example, 16% of the NHDS discharges 
for 2010 and 23% of NAMCS records in 2010 lacked 
information about the racial status of the patient. 
Medicare and death certiﬁ cate data represented the 
only data that allowed trend analyses for American 
Indian/Alaska Natives, Hispanics, and Asian popula-
tions. Because race and ethnicity designations are 
subject to misclassiﬁ cation, 34 caution is urged in inter-
 Figure 9. Age-speciﬁ c death rates (per 100,000) for COPD as the underlying cause of death among 
adults aged   25 years, by year—United States, Mortality Component of the National Vital Statistics 
System, 1999-2010. 
 Figure 10. Race-speciﬁ c age-adjusted death rates (per 100,000) for COPD as the underlying cause of 
death among adults aged   25 years, by year—United States, Mortality Component of the National Vital 
Statistics System, 1999-2010. 
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 Healthy People objectives provide science-based, 
10-year national objectives for improving the health 
of all Americans; identify nationwide health improve-
ment priorities; and strive to engage multiple sectors 
(public health agencies, communities, organizations, 
academia, and medicine) to take actions to strengthen 
versions of Global Strategy for Diagnosis, Manage-
ment, and Prevention of COPD. 24 Several studies 
have reported imperfect implementation of the GOLD 
guidelines in clinical practice. 35 Additional efforts may 
be needed to educate physicians about the manage-
ment of this condition. 
 Table 17— Annual Number of Adults Aged   25 Years With COPD as the Underlying Cause of Death, by State—United 
States, Mortality Component of the National Vital Statistics System, 1999-2010 
State 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Alabama 2,095 1,964 2,125 2,245 2,347 2,256 2,318 2,239 2,463 2,655 2,693 2,784
Alaska 133 125 134 132 132 128 145 129 164 176 187 165
Arizona 2,414 2,410 2,382 2,462 2,448 2,328 2,723 2,695 2,605 2,860 2,773 2,836
Arkansas 1,296 1,328 1,297 1,383 1,439 1,375 1,508 1437 1,587 1,833 1,772 1,732
California 12,488 12,092 12,356 12,088 12,833 11,971 12,608 12,223 11,995 12,870 12,393 12,455
Colorado 1,791 1,715 1,762 1,773 1,864 1,823 1,864 1,873 1,948 2,128 2,012 2,143
Connecticut 1,366 1,469 1,429 1,385 1,395 1,375 1,421 1,400 1,310 1,461 1,389 1,237
Delaware 316 322 286 335 333 334 398 338 370 460 421 427
District of 
Columbia
150 160 138 125 126 144 123 114 122 133 127 139
Florida 8,815 8,345 8,621 8,738 8,778 8,703 9,173 8,668 9,092 9,957 9,891 10,076
Georgia 2,903 2,914 2,950 3,032 3,105 2,980 3,262 3,241 3,269 3,426 3,615 3,694
Hawaii 250 233 243 234 249 270 260 258 260 266 269 265
Idaho 542 549 562 574 575 544 691 624 639 682 699 701
Illinois 4,851 4,486 4,499 4,539 4,601 4,493 4,817 4,521 4,552 5,384 5,093 4,998
Indiana 2,915 2,948 3,053 3,032 3,167 3,030 3,365 3,193 3,130 3,768 3,649 3,697
Iowa 1,574 1,454 1,482 1,521 1,620 1,492 1,650 1,603 1,605 1,803 1,777 1,633
Kansas 1,323 1,351 1,393 1,328 1,407 1,272 1,529 1,447 1,437 1,581 1,537 1,532
Kentucky 2,260 2,090 2,204 2,339 2,327 2,202 2,507 2,331 2,577 2,874 2,791 2,721
Louisiana 1,525 1,591 1,684 1,598 1,660 1,547 1,830 1,630 1,633 1,831 1,826 1,895
Maine 730 755 773 769 762 744 813 763 717 774 801 788
Maryland 1,836 1,828 1,813 1,838 1,887 1,808 1,823 1,761 1,813 1,916 1,980 1,955
Massachusetts 2,729 2,799 2,699 2,630 2,668 2,466 2,529 2,457 2,260 2,510 2,481 2,306
Michigan 4,130 4,150 3,974 4,251 4,316 4,099 4,304 4,334 4,466 5,050 4,814 4,943
Minnesota 1,880 1,794 1,816 1,864 1,742 1,762 1,883 1,706 1,686 2,023 1,879 1,923
Mississippi 1,217 1,189 1,275 1,320 1,352 1,295 1,416 1,324 1,363 1,464 1,505 1,602
Missouri 2,949 2,692 2,781 2,765 2,836 2,628 3,002 2,922 2,990 3,663 3,354 3,453
Montana 538 499 559 554 568 563 569 561 595 681 588 586
Nebraska 893 794 831 885 851 774 897 845 882 1,009 945 976
Nevada 987 959 1,108 1,149 1,155 1,097 1,209 1,046 1,027 1,233 1,215 1,155
New Hampshire 578 560 596 553 509 581 611 589 593 676 640 594
New Jersey 2,993 2,874 2,761 2,737 2,775 2,895 3,009 2,732 2,881 3,159 3,010 2,998
New Mexico 810 725 734 815 893 722 824 857 852 973 955 996
New York 6,653 6,419 6,514 6,581 6,336 6,430 6,472 6,047 6,281 6,619 6,440 6,509
North Carolina 3,412 3,533 3,343 3,531 3,725 3,474 4,005 3,858 4,071 4,413 4,196 4,357
North Dakota 256 280 298 306 284 260 260 274 255 341 330 341
Ohio 5,656 5,773 5,686 5,840 5,739 5,727 6,406 5,871 6,263 6,771 6,479 6,520
Oklahoma 1,683 1,906 1,853 1,920 2,093 1,923 2,296 2,133 2,333 2,645 2,539 2,679
Oregon 1,664 1,599 1,646 1,754 1,738 1,711 1,767 1,730 1,816 1,868 1,847 1,888
Pennsylvania 5,922 5,837 5,646 5,797 5,816 5,774 5,935 5,420 5,871 6,531 6,254 6,025
Rhode Island 478 493 494 509 474 447 502 467 406 462 500 498
South Carolina 1,675 1,645 1,640 1,805 1,819 1,699 1,879 1,854 1,949 2,176 2,245 2,175
South Dakota 315 364 335 364 365 375 424 363 437 474 431 430
Tennessee 2,655 2,765 2,826 2,874 2,939 2,885 3,076 2,875 3,064 3,462 3,408 3,460
Texas 7,139 6,960 7,404 7,400 7,264 7,110 7,666 7,334 7,814 8,605 8,365 8,667
Utah 523 482 483 555 525 549 559 548 589 604 547 637
Vermont 288 295 298 267 295 286 370 308 307 330 353 322
Virginia 2,549 2,667 2,607 2,620 2,840 2,607 2,770 2,592 2,656 2,899 2,901 2,865
Washington 2,604 2,533 2,520 2,604 2,545 2,448 2,591 2,553 2,597 2,832 2,835 2,634
West Virginia 1,208 1,300 1,242 1,195 1,257 1,207 1,315 1,233 1,289 1,567 1,462 1,455
Wisconsin 2,172 2,202 2,286 2,246 2,223 2,220 2,352 2,273 2,325 2,455 2,397 2,384
Wyoming 327 277 256 319 270 301 279 329 285 304 307 324
Total 118,456 116,494 117,697 119,480 121,267 117,134 126,005 119,923 123,491 136,637 132,917 133,575
COPD includes ICD-10 Codes J40–J44 from the WHO. See Table 15 legend for expansion of abbreviations.
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 Table 18— Age-Adjusted Annual Rates for Deaths With COPD as the Underlying Cause of Death Among Adults 
Aged   25 Years, by State—United States, Mortality Component of the National Vital Statistics System, 1999-2010 
State a 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010  P for Linear Trend
Alabama 72.2 67.1 72.0 75.5 78.1 74.2 75.4 71.3 77.2 81.4 81.5 83.2 .002
Alaska 81.1 71.0 74.3 69.2 67.0 57.7 62.3 55.2 67.6 67.2 73.6 60.6 .202
Arizona 74.9 73.2 70.3 71.4 68.9 63.8 71.6 68.5 64.4 68.5 64.5 64.5 .003
Arkansas 68.9 70.0 68.0 72.0 74.3 70.3 76.3 71.2 77.8 88.1 83.9 80.8 .001
California 68.9 65.6 65.5 63.0 65.4 60.2 61.9 59.2 56.8 59.3 55.7 54.9  , .001
Colorado 85.4 80.4 80.3 78.9 80.8 77.0 76.8 74.1 74.4 79.1 71.8 75.0 .002
Connecticut 55.5 59.3 56.7 54.3 53.8 52.5 53.7 51.9 48.3 53.0 49.6 43.6  , .001
Delaware 63.8 64.3 55.4 64.0 61.6 60.4 70.0 57.5 61.0 73.5 65.9 65.8 .236
District of 
Columbia
41.7 44.2 38.3 34.5 35.1 40.3 34.7 32.4 34.2 37.4 35.2 37.7 .099
Florida 64.0 60.0 61.1 60.7 60.1 58.4 60.3 56.3 57.8 61.9 60.3 60.3 .338
Georgia 72.5 72.0 71.4 71.6 72.3 67.7 71.9 68.8 67.7 68.1 70.1 70.0 .030
Hawaii 31.9 29.0 29.4 27.4 28.4 29.9 27.7 27.1 26.7 27.0 26.1 24.8  , .001
Idaho 73.1 72.9 72.7 72.7 70.9 65.6 80.6 70.4 69.9 72.4 71.8 70.1 .597
Illinois 63.0 57.9 57.6 57.6 57.9 56.1 59.4 55.3 55.0 64.2 59.9 58.2 .908
Indiana 76.2 76.6 78.4 77.0 79.2 75.1 82.1 76.6 73.9 87.2 83.6 83.3 .060
Iowa 69.3 63.6 64.2 66.0 69.6 63.6 70.3 67.6 66.4 74.3 73.0 66.2 .157
Kansas 71.8 72.6 74.7 70.8 74.6 67.1 79.4 74.4 73.1 79.4 76.0 75.0 .155
Kentucky 88.6 81.5 85.2 89.4 87.9 82.3 91.6 83.3 90.7 99.0 94.1 90.7 .050
Louisiana 59.0 61.0 63.9 60.1 61.4 56.9 66.3 61.0 60.1 65.8 64.1 65.9 .072
Maine 79.0 80.5 81.1 79.5 77.2 74.5 80.5 73.9 67.7 72.0 73.3 71.3 .002
Maryland 61.0 60.1 58.2 57.9 58.2 54.8 54.0 51.3 52.0 53.5 53.8 52.0  , .001
Massachusetts 61.3 62.3 59.6 57.6 58.0 53.2 54.0 52.1 47.4 51.8 50.6 46.5  , .001
Michigan 67.0 66.8 63.1 66.5 66.5 62.3 64.6 64.1 64.8 72.0 67.4 68.6 .271
Minnesota 60.2 56.9 57.1 57.4 52.8 52.9 55.6 49.6 48.3 56.5 51.6 51.9 .015
Mississippi 70.1 68.1 72.6 74.7 76.1 71.8 77.4 71.9 73.0 76.7 78.7 82.3 .004
Missouri 76.7 69.7 71.2 70.2 71.4 65.5 74.0 70.9 71.3 86.3 77.8 78.8 .097
Montana 87.3 80.0 87.9 85.9 86.9 84.1 83.1 79.9 83.2 92.9 78.5 77.2 .218
Nebraska 73.8 66.1 67.8 71.8 69.2 62.0 71.3 66.0 68.2 76.9 71.5 73.1 .389
Nevada 96.5 92.1 99.2 100.0 95.9 86.7 92.2 76.5 74.0 85.7 80.6 74.9 .001
New 
Hampshire
77.0 73.6 77.0 70.3 63.4 69.9 72.3 67.7 66.4 74.2 69.2 62.9 .053
New Jersey 53.0 50.4 47.9 46.9 47.1 48.7 50.1 44.9 46.7 50.4 47.3 46.8 .186
New Mexico 78.2 68.6 67.3 73.1 78.8 62.2 68.8 69.4 67.3 74.7 70.7 71.8 .816
New York 53.6 51.0 51.1 50.9 48.5 48.8 48.6 45.1 46.3 48.1 46.4 46.2  , .001
North Carolina 70.6 72.3 67.1 69.3 71.5 65.1 73.4 68.0 69.8 73.5 68.0 69.1 .897
North Dakota 51.9 56.6 59.1 61.4 56.5 51.1 50.8 51.7 48.7 64.3 62.2 63.8 .383
Ohio 74.4 75.5 73.7 74.8 72.6 71.8 79.4 71.8 75.5 80.5 75.9 75.7 .291
Oklahoma 73.2 82.2 79.5 81.7 88.4 80.7 95.3 86.6 93.8 104.4 98.3 102.6  , .001
Oregon 73.5 70.0 70.7 73.8 71.7 69.5 70.0 66.8 68.4 68.9 66.6 67.1 .001
Pennsylvania 61.1 59.7 57.4 58.5 58.1 57.6 58.5 52.9 56.7 62.4 59.4 56.8 .463
Rhode Island 60.5 61.5 61.7 62.6 57.5 54.2 60.2 56.8 48.4 55.8 60.2 58.4 .147
South Carolina 69.5 67.4 65.7 71.2 69.7 63.7 68.6 65.2 66.5 72.0 72.2 68.6 .478
South Dakota 55.9 64.0 59.5 63.6 63.7 63.5 71.5 59.8 70.9 75.5 68.0 67.8 .012
Tennessee 74.6 77.1 77.6 77.8 78.3 75.7 79.0 71.7 74.8 82.6 79.5 79.3 .298
Texas 69.0 66.3 69.2 68.0 65.2 62.5 65.6 60.8 63.1 67.8 63.8 64.8 .105
Utah 54.4 49.4 48.2 54.3 50.1 50.8 50.3 47.3 49.0 48.9 43.1 48.8 .031
Vermont 73.2 73.9 73.3 64.4 70.0 67.1 85.7 69.2 67.5 71.2 74.0 67.3 .729
Virginia 64.2 66.2 63.5 62.3 66.5 59.8 61.9 56.5 56.8 60.3 59.0 56.9 .002
Washington 76.2 73.1 71.2 72.1 69.2 65.1 67.4 64.6 64.1 68.1 66.4 60.3  , .001
West Virginia 87.4 93.8 89.3 85.1 88.5 84.6 91.1 84.6 87.0 104.9 96.8 95.1 .138
Wisconsin 59.8 60.3 61.8 59.8 58.5 57.8 60.4 57.5 57.8 59.7 58.0 56.5 .019
Wyoming 113.4 94.6 85.1 104.6 86.7 94.8 85.4 99.4 84.6 88.4 87.8 89.6 .119
Total a 67.0 65.2 64.9 65.0 64.9 61.8 65.3 61.1 61.7 66.9 63.8 63.1 .163
Annual rate per 100,000 US population. COPD includes ICD-10 codes J40–J44 from the WHO. Death rates for 2001-2009 will differ from previous 
reports because 2001-2009 population denominators have been revised in CDC Wonder (Oct 2012). See Table 15 legend for expansion of 
abbreviations.
 a Age-adjusted to the 2000 US population aged   25 y.
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policies and improve practices that are driven by the 
best available evidence and knowledge. The Healthy 
People 2010 objective for COPD called for a 50% 
reduction in the mortality rate from COPD among 
adults aged   45 years at baseline in 1999 (123.9 per 
100,000) 36 ; however, that objective was not met by 
2010 (116.6 per 100,000)—possibly for many reasons 
described above. The new Healthy People 2020 effort 37 
has been expanded to include the following objec-
tives that pertain to the evaluation and management 
of COPD among adults aged   45 years: 
  • Reduce activity limitations among adults with 
  COPD. 
  • Reduce deaths from COPD. 
  • Reduce hospitalizations for COPD. 
  • Reduce hospital ED visits for COPD 
  • Increase the proportion of adults with abnormal 
   lung function whose underlying obstructive 
disease has been diagnosed. 
 The CDC and the National Heart Lung Blood Insti-
tute (NHLBI) have a formal collaboration to increase 
 Figure 11. Age-adjusted state-speciﬁ c death rates (per 100,000) for COPD as the underlying cause of 
death among adults aged   25 years, by state—United States, Mortality Component of the National 
Vital Statistics System, 1999-2000 and 2009-2010. 
  
 Figure 12. Signiﬁ cant linear change ( P  , .05) in state-speciﬁ c 
age-adjusted death rates for COPD as the underlying cause of 
death among adults aged   25 years, by state—United States, 
Mortality Component of the National Vital Statistics System, 
1999-2010. 
  
public awareness and identify critical communication, 
research, evaluation, and data collection needs to 
prevent and manage COPD. This collaboration has 
resulted in the annual BRFSS collection since 2011 
of COPD prevalence data at state and local levels, 
which will enhance the COPD Learn More Breathe 
Better Campaign supported by the NHLBI. Such 
state-level and county-level data as the BRFSS, Medi-
care, and vital statistics can identify geographic clus-
tering of, as well as racial/ethnic disparities in, COPD 
indicators to provide guidance to public health agencies 
in leveraging and targeting resources to those geo-
graphic areas and local populations with the greatest 
burden of COPD. These data will also be critical in 
identifying communities that will likely beneﬁ t best 
from awareness and outreach campaigns and in eval-
uating the effectiveness of public health efforts to 
prevent, treat, and control COPD. 
 COPD remains a signiﬁ cant source of morbidity 
and mortality in the United States. In 2007, chronic 
lower respiratory diseases constituted the fourth lead-
ing cause of death and rose to the third leading cause 
of death in 2008 primarily because cerebrovascular 
disease deaths continued a consistent decline and to 
a lesser extent as a result of adjustments to coding 
and classiﬁ cation. 1 The data examined in this surveil-
lance report testify to the heavy public health burden 
that COPD continues to levy in the United States. 
Prior to 1999, rates of mortality and hospitalizations 
had shown worrisome increases. Thus, the apparent 
leveling of the mortality rate and a decrease in the 
rate of hospitalization represent cause for cautious 
optimism. Future surveillance efforts will be critical 
to tracking the course of COPD in the United States. 
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